During the past decade, Peking University Shenzhen Hospital conducted 81 clinical trials. In the 10-year time frame, 81 clinical trials started and 10 clinical trials were completed, i.e. on average, 12.3% percent of trials that started reached the finish line to date. In the past 5 years, 51 clinical trials started and 9 clinical trials were completed. i.e. 17.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Peking University Shenzhen Hospital" #1 sponsor was "iCell Gene Therapeutics" with 7 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "Peking University Shenzhen Hospital" with 5 trials sponsored, "Shanghai Junshi Bioscience Co., Ltd." with 4 trials sponsored and "Takeda" with 4 trials sponsored. Other sponsors include 60 different institutions and companies that sponsored additional 54 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Peking University Shenzhen Hospital" #1 collaborator was "Peking University Shenzhen Hospital" with 15 trials as a collaborator, "iCAR Bio Therapeutics Ltd." with 7 trials as a collaborator, "Chengdu Military General Hospital" with 3 trials as a collaborator, "First Affiliated Hospital of Guangxi Medical University" with 3 trials as a collaborator and "Nanfang Hospital of Southern Medical University" with 3 trials as a collaborator. Other collaborators include 164 different institutions and companies that were collaborators in the rest 157 trials.

According to Clinical.Site data, the most researched conditions in "Peking University Shenzhen Hospital" are "Acute Ischemic Stroke" (2 trials), "Acute Myeloid Leukemia" (2 trials), "Bacterial Vaginosis" (2 trials), "Breast Cancer" (2 trials) and "Cervical Intraepithelial Neoplasia" (2 trials). Many other conditions were trialed in "Peking University Shenzhen Hospital" in a lesser frequency.

Most popular intervention types in "Peking University Shenzhen Hospital" are "Drug" (60 trials), "Biological" (13 trials), "Other" (8 trials), "Procedure" (8 trials) and "Device" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Capecitabine" (4 trials), "Cisplatin" (3 trials), "Lansoprazole" (3 trials) and "Lansoprazole Placebo" (3 trials). Other intervention names were less common.

The vast majority of trials in "Peking University Shenzhen Hospital" are 70 trials for "All" genders, 17 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Peking University Shenzhen Hospital". 1 are not yet recruiting, 38 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Peking University Shenzhen Hospital, 1 suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Peking University Shenzhen Hospital, 6 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 12 trials that are defined as “Not Applicable".